These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 3277911)
1. Role of thromboxane A2 in the hypotensive effect of captopril in essential hypertension. Kudo K; Abe K; Chiba S; Sato M; Yasujima M; Kohzuki M; Omata K; Tanno M; Tsunoda K; Yoshinaga K Hypertension; 1988 Feb; 11(2):147-52. PubMed ID: 3277911 [TBL] [Abstract][Full Text] [Related]
2. Effects of OKY-046, a selective thromboxane synthetase inhibitor, on blood pressure and thromboxane synthesis in spontaneously hypertensive rats. Gomi T; Ikeda T; Ishimitsu T; Uehara Y Prostaglandins Leukot Essent Fatty Acids; 1989 Sep; 37(3):139-44. PubMed ID: 2608692 [TBL] [Abstract][Full Text] [Related]
3. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects. Morio H; Hirai A; Terano T; Tamura Y; Yoshida S Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052 [TBL] [Abstract][Full Text] [Related]
4. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation. Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196 [TBL] [Abstract][Full Text] [Related]
5. Preliminary observations of the acute effects of selective serum thromboxane inhibition and angiotensin converting enzyme inhibition on blood pressure and renal hemodynamics in hypertensive humans. Weir MR; Klassen DK; Hoover N; Douglas FL J Clin Pharmacol; 1989 Dec; 29(12):1108-16. PubMed ID: 2693500 [TBL] [Abstract][Full Text] [Related]
6. Effects of OKY 046, a thromboxane-synthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites. Gentilini P; Laffi G; Meacci E; La Villa G; Cominelli F; Pinzani M; Buzzelli G Gastroenterology; 1988 Jun; 94(6):1470-7. PubMed ID: 3360268 [TBL] [Abstract][Full Text] [Related]
7. Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy. Hora K; Oguchi H; Furukawa T; Hora K; Tokunaga S Nephron; 1990; 56(3):297-305. PubMed ID: 2077412 [TBL] [Abstract][Full Text] [Related]
8. Thromboxane A2 and the development of hypertension in spontaneously hypertensive rats. Stier CT; Itskovitz HD Eur J Pharmacol; 1988 Jan; 146(1):129-35. PubMed ID: 3350054 [TBL] [Abstract][Full Text] [Related]
9. [The influence of sodium ferulate on hypotensive effect and urinary excretion of TXB2 after captopril in essential hypertensive patients]. Xu XY; Wang Q Zhong Xi Yi Jie He Za Zhi; 1991 Nov; 11(11):657-8, 644. PubMed ID: 1667512 [TBL] [Abstract][Full Text] [Related]
10. Thromboxane A2 and development of genetic hypertension in the Lyon rat strain. Geoffroy J; Benzoni D; Vincent M; Sassard J Hypertension; 1990 Dec; 16(6):655-61. PubMed ID: 2147173 [TBL] [Abstract][Full Text] [Related]
12. The combined use of prostaglandin I2 analogue (OP-2507) and thromboxane A2 synthetase inhibitor (OKY-046) strongly inhibits atherosclerosis of aortic allografts in rats. Hirano T; Nakafusa Y; Kawano R; Motoyama K; Arima T; Sugitani A; Tanaka M Surgery; 2001 May; 129(5):595-605. PubMed ID: 11331452 [TBL] [Abstract][Full Text] [Related]
13. Renal effects of the inhibitor of thromboxane A2-synthetase OKY-046. Hatziantoniou C; Papanikolaou N Experientia; 1986 Jun; 42(6):613-5. PubMed ID: 3522267 [TBL] [Abstract][Full Text] [Related]
14. In vivo enhancement of platelet activating factor-induced prostacyclin production by OKY-046, a selective inhibitor of thromboxane A2 synthase. Davenport NJ; Goldstein RE; Feuerstein GZ J Cardiovasc Pharmacol; 1991 Apr; 17(4):641-6. PubMed ID: 1711633 [TBL] [Abstract][Full Text] [Related]
15. Role of thromboxane (Tx) A2 in guinea pig Forssman shock and the effect of OKY-046, Tx A2 synthetase inhibitor. Nagai H; Yakuo I; Inagaki N; Koda A; Hamano S; Ujiie A; Nakazawa M Prostaglandins Leukot Med; 1987 Feb; 26(2):133-41. PubMed ID: 3470814 [TBL] [Abstract][Full Text] [Related]
16. Effect of captopril on urinary excretion of prostaglandins and renin-angiotensin-aldosterone system in normal subjects. Zacharieva S; Koev D; Andonova K Acta Physiol Pharmacol Bulg; 1989; 15(4):25-30. PubMed ID: 2699540 [TBL] [Abstract][Full Text] [Related]
17. Role of pressor prostanoids in rats with angiotensin II-salt-induced hypertension. Mistry M; Nasjletti A Hypertension; 1988 Jun; 11(6 Pt 2):758-62. PubMed ID: 3164706 [TBL] [Abstract][Full Text] [Related]
18. Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581. Casey LC; Fletcher JR; Zmudka MI; Ramwell PW J Pharmacol Exp Ther; 1982 Aug; 222(2):441-6. PubMed ID: 6896528 [TBL] [Abstract][Full Text] [Related]
19. Effects of captopril on prostaglandin and natriuresis in patients with essential hypertension. Hornych A; Safar M; Simon A; Levenson J; Bariety J; Milliez P Am J Cardiol; 1982 Apr; 49(6):1524-6. PubMed ID: 7041590 [TBL] [Abstract][Full Text] [Related]
20. Urinary excretion of TXB2 after angiotensin converting enzyme inhibition in hypertensive patients. Kudo K; Abe K; Chiba S; Omata K; Sato K; Yasugima M; Sato M; Yoshinaga K Prostaglandins Leukot Med; 1986 Jan; 21(1):77-86. PubMed ID: 3006084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]